[ad_1]
Pulmonx shares soar 118% in trading debut
Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company’s initial public offering priced above range. The deal priced at $19 a share, abo…
[ad_2]